Liver Diseases Therapeutics
1. Iqirvo patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or as monotherapy in patients unable to tolerate u...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12310935 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295928 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295927 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(1 year, 3 months ago) | |
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
2. Livdelzi patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709682 | GILEAD SCIENCES INC | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives |
Sep, 2026
(8 months from now) | |
| US7301050 | GILEAD SCIENCES INC | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
Aug, 2026
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596614 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US11406611 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US10272058 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US9486428 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Aug 14, 2031 |
Drugs and Companies using SELADELPAR LYSINE ingredient
NCE-1 date: 14 August, 2028
Market Authorisation Date: 14 August, 2024
Dosage: CAPSULE
More Information on Dosage
LIVDELZI family patents
3. Livmarli patent
expiration
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs); Treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis...
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497745 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(5 years from now) | |
| US11229661 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| US10512657 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US12350267 | MIRUM | NA |
Oct, 2032
(6 years from now) | |
| US12296050 | MIRUM | Pharmaceutical compositions comprising maralixibat and uses thereof |
Oct, 2043
(17 years from now) | |
| US11918578 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| ODE*(ODE*) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-471) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-490) | Jul 24, 2031 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 10 April, 2025
Dosage: TABLET; SOLUTION
More Information on Dosage
LIVMARLI family patents
4. Ocaliva patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as mono...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7138390 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Nov, 2022
(3 years ago) | |
| US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(7 years from now) | |
| USRE48286 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2027
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8058267 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(3 years ago) | |
| US8377916 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(3 years ago) | |
| US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(7 years from now) | |
| US10758549 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US10751349 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US10052337 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-119) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Dosage: TABLET
How can I launch a generic of OCALIVA before it's drug patent expiration?
More Information on Dosage
OCALIVA family patents
5. Rezdiffra patent expiration
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11564926 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US9266861 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US7452882 | MADRIGAL | Thyroid hormone analogs |
Sep, 2026
(8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986481 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US10376517 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US12377104 | MADRIGAL | NA |
Feb, 2045
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents